Dr. Corey J. Langer

Doctor Overview

Dr. Corey Langer is a board-certified thoracic oncologist in Philadelphia. He is the director of thoracic oncology at the Hospital of the University of Pennsylvania. He treats mesothelioma patients at the renowned Penn Mesothelioma and Pleural Program. The program offers patients access to the latest mesothelioma treatments and clinical trials.

Before coming to Philadelphia, Dr. Langer graduated from Boston University’s School of Medicine. He then completed his residency in internal medicine at Graduate Hospital. He completed his fellowships in hematology and oncology at Penn Presbyterian Medical Center and medical oncology at Fox Chase Cancer Center.

After more than 35 years in the field, Dr. Langer is a leading expert in thoracic oncology. He has worked on over 140 clinical trials throughout his career, with a focus on underserved communities. His clinical expertise includes non-small cell lung cancer and small cell lung cancer, mesothelioma and immunotherapy. His research has also focused on novel therapeutic venues in thoracic and head and neck cancers.

In addition to Dr. Langer’s clinical work, he has published over 300 articles in many peer-reviewed journals, including Journal of Thoracic Oncology, Cancer and Clinical Lung Cancer.

Doctor Fast Facts

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Malignant pleural mesothelioma, malignant peritoneal mesothelioma, adenocarcinoma of the lung, pleural cancer, lung cancer, lung carcinoid tumor, head and neck cancer, esophageal cancer and immunotherapy.

Certifications, Awards & Accolades: American Board of Internal Medicine certifications in Hematology, Internal Medicine and Medical Oncology, America’s Top Doctors, America’s Top Doctors for Cancer, Best Doctors in America, Philadelphia Magazine Top Doctor, Castle Connolly America’s Top Doctors, Castle Connolly America’s Top Doctors for Cancer

Education & Experience:

• Medical Degree from Boston University School of Medicine
• Residency in Internal Medicine at Graduate Hospital
• Fellowship in Hematology and Oncology at Penn Presbyterian Medical Center
• Fellowship in Medical Oncology at Fox Chase Cancer Center

Publications

Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. Radiother Oncol. 2024 Jan;190:110005.

Tumor Treating Fields therapy in metastatic non-small-cell lung cancer – Authors’ reply. Lancet Oncol. 2023 Dec;24(12):e454.

Plunging into the pacific: outcomes of patients with unresectable kras-mutated non-small cell lung cancer following definitive chemoradiation and durvalumab consolidation. Clin Lung Cancer. 2023 Dec 22;S1525-7304(23)00266-8.

Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med. 2023 Jun;12(11):12208–20.

Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma. JAMA Netw Open. 2023 Mar 1;6(3):e232526.

A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLoS One. 2022;17(9):e0275187.